- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
18matching registry records
Matching recruiting site observations2
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 / HF-POLARIS / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 35,610 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 23, 2029estimated | Jul 15, 2026ClinicalTrials.gov | Open NCT07567001 ↗ |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 32,500 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 23, 2028estimated | Jul 8, 2026ClinicalTrials.gov | Open NCT07564414 ↗ |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 / MARITIME-CV / Amgen | RecruitingVerified 2026-07 | Phase 312,800 estimated | 1 matching recruitingWausau, Wisconsin, 54401, United States | Jun 30, 2028estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07037433 ↗ |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 / MARITIME-HF / Amgen | RecruitingVerified 2026-06 | Phase 35,056 estimated | 1 matching recruitingMilwaukee, Wisconsin, 53215, United States | Jun 30, 2028estimated | Jul 2, 2026ClinicalTrials.gov | Open NCT07037459 ↗ |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 / REDEFINE 3 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 37,101 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 1, 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT05669755 ↗ |
| Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 / MARITIME-1 / Amgen | Active, not recruitingVerified 2025-10 | Phase 33,853 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 21, 2027estimated | Oct 20, 2025ClinicalTrials.gov | Open NCT06858839 ↗ |
| Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711 / Amgen | Active, not recruitingVerified 2026-07 | Phase 149 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 18, 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07523711 ↗ |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 310,000 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 2029estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06383390 ↗ |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 / REIMAGINE 2 / Novo Nordisk A/S | CompletedVerified 2026-07 | Phase 32,734 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 19, 2025actual | Jul 8, 2026ClinicalTrials.gov | Open NCT06065540 ↗ |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 2626 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 24, 2025actual | Apr 1, 2026ClinicalTrials.gov | Open NCT06131372 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 / Novo Nordisk A/S | CompletedVerified 2026-04 | Phase 31,024 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 4, 2026actual | Apr 22, 2026ClinicalTrials.gov | Open NCT06221969 ↗ |
| A Study of LY3841136 in Healthy and Overweight ParticipantsNCT05295940 / Eli Lilly and Company | CompletedVerified 2024-03 | Phase 1148 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 25, 2024actual | Apr 1, 2024ClinicalTrials.gov | Open NCT05295940 ↗ |
| A Study of LY3841136 in Overweight and Obese ParticipantsNCT06345066 / Eli Lilly and Company | CompletedVerified 2025-10 | Phase 196 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 29, 2025actual | Oct 15, 2025ClinicalTrials.gov | Open NCT06345066 ↗ |
| Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsNCT07226778 / Amgen | CompletedVerified 2026-06 | Phase 1348 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 28, 2026actual | Jun 17, 2026ClinicalTrials.gov | Open NCT07226778 ↗ |
| A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityNCT07717814 / Amgen | CompletedVerified 2026-07 | Phase 1154 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 22, 2025actual | Jul 21, 2026ClinicalTrials.gov | Open NCT07717814 ↗ |
| A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male ParticipantsNCT05757531 / Eli Lilly and Company | CompletedVerified 2023-07 | Phase 17 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 23, 2023actual | Jul 5, 2023ClinicalTrials.gov | Open NCT05757531 ↗ |
| A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightNCT04667377 / Boehringer Ingelheim | CompletedVerified 2023-10Registry results posted | Phase 2387 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 15, 2022actual | Nov 2, 2023ClinicalTrials.gov | Open NCT04667377 ↗ |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 / Boehringer Ingelheim | CompletedVerified 2026-07 | Phase 35,531 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 1, 2026actual | Jul 23, 2026ClinicalTrials.gov | Open NCT06077864 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →